Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 8/20 | 0.62 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | AGXT | P21549 | 1/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721910 | 0.86 | CHKA (0.57) | AOC3AGXTMEN1NPC1ALDH1A1 | |
| SCHEMBL12523755 | 0.85 | AOC3 (0.59) | AOC3AGXTPRKDCCNR2HSD17B1 | |
| SCHEMBL108136 | 0.84 | AGXT (0.69) | AOC3NCF1AGXTADRA2AADRA2B | |
| SCHEMBL3728010 | 0.84 | AOC3 (0.66) | AOC3AGXTADRA2CALDH1A1MAPT | |
| SCHEMBL3719689 | 0.82 | NCF1 (0.73) | NCF1NPC1ALDH1A1HTTRAB9A | |
| SCHEMBL39888 | 0.82 | LMNA (0.52) | AOC3NCF1AGXTCNR2MEN1 | |
| SCHEMBL12525685 | 0.80 | AOC3 (0.65) | AOC3NCF1CNR2 | |
| SCHEMBL11427269 | 0.80 | AOC3 (0.64) | AOC3HTT | |
| SCHEMBL14320480 | 0.80 | JAK2 (0.55) | AOC3AGXTPRKDCFYNCNR2 | |
| SCHEMBL10320681 | 0.78 | AOC3 (1.00) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | claimed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | claimed |
| EP-3002278-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-04-19 | — | — | EP | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| US-9556160-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2017-01-31 | — | — | US | disclosed |
| EP-2695881-B1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-27 | — | — | EP | disclosed |
| EP-3002278-A1 | GUANIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2016-04-06 | — | — | EP | disclosed |
| US-20150203480-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150203480-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2015-07-23 | — | — | US | disclosed |
| US-9051283-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051283-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | disclosed |
| US-20130143860-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-06-06 | — | — | US | disclosed |
| WO-2012124696-A1 | GUANIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2012-09-20 | — | — | WO | disclosed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143860-A1 | GUANIDINE COMPOUND | GUCY1A1, VAPA, VAPB | AOC3 700/4885NCF1 1903/4885AGXT 2111/4885 |
| US-20150203480-A1 | GUANIDINE COMPOUND | GUCY1A1, VAPA, VAPB | AOC3 700/4885NCF1 1903/4885AGXT 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.